Results 271 to 280 of about 531,557 (374)

Disruption of Dopamine Homeostasis Associated with Alteration of Proteins in Synaptic Vesicles: A Putative Central Mechanism of Parkinson's Disease Pathogenesis. [PDF]

Aging Dis
Jin X, Si X, Lei X, Liu H, Shao A, Li L.
europepmc   +1 more source

Synaptic Vesicle Recycling in Cultured Cerebellar Granule Cells: Role of Vesicular Acidification and Refilling [PDF]

, 1997
Michael A. Cousin, David G. Nicholls
openalex   +1 more source

Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach

Movement Disorders, EarlyView.
ABSTRACT Neuroimaging with positron emission tomography (PET) has been instrumental in elucidating neurobiological mechanisms behind therapeutical trials in Parkinson's disease (PD). A variety of medical and neurosurgical interventions have been evaluated using many radioligands that reveal molecular basis for target engagement and brain responses in ...
Vijay Dhawan, Shichun Peng, Phoebe G. Spetsieris, David Eidelberg, Yilong Ma   +4 more
wiley   +1 more source

Synaptotagmin 7 docks synaptic vesicles to support facilitation and Doc2α-triggered asynchronous release. [PDF]

Elife
Wu Z, Kusick GF, Berns MMM, Raychaudhuri S, Itoh K, Walter AM, Chapman ER, Watanabe S.   +7 more
europepmc   +1 more source

BACE1 controls synaptic function through modulating release of synaptic vesicles. [PDF]

Mol Psychiatry, 2021
Das B, Singh N, Yao AY, Zhou J, He W, Hu X, Yan R.   +6 more
europepmc   +1 more source

A morphometric analysis of isolated Torpedo electric organ synaptic vesicles following stimulation. [PDF]

, 1990
Dowe, G., Fox, G., Koetting, D.
core  

Secretory vesicle and cell surface markers for human endocrine pancreatic and pituiary tumors [PDF]

, 1992
Gratzl, Manfred, Gratzl, O., Lahr, G., Langley, K., Vereczkey, C.   +4 more
core   +1 more source

Endocytosis of VAMP is facilitated by a synaptic vesicle targeting signal. [PDF]

, 1996
Eric Grote, R B Kelly
openalex   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

Movement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian, A. Jon Stoessl, Anthony E. Lang   +2 more
wiley   +1 more source

Physical presence of chemical synapses is necessary for turning behavior of anterograde synaptic vesicles at the branch point of PLM neurons in C. elegans. [PDF]

MicroPubl Biol
Vasudevan A, Koushika SP.
europepmc   +1 more source